Forget the glorious successes of past breakthroughs—the real justification for research investment is what we get for our ...

To answer that, in several recent papers, economists have approached this issue in clever new ways. And, though they ask ...

BioMarin Pharma has decided not to divest its haemophilia A gene therapy Roctavian, which has struggled to build much traction in the market, but is reining back its ambitions for the business. The ...